Form 4: Director William Rastetter Receives NBIX Equity Grant

Neurocrine Biosciences director William H. Rastetter was granted 2,567 restricted stock units vesting in May 2027.

Summary

• Director William H. Rastetter acquired 2,567 restricted stock units (RSUs) of Neurocrine Biosciences, Inc. (NBIX).
• Each RSU represents the right to receive one share of common stock upon vesting.
• The grant was issued on May 27, 2026, with a full vesting date scheduled for May 27, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard equity compensation disclosure for a board member.

Risks

• Standard market risks associated with equity ownership and potential volatility in NBIX share price.

Future Outlook

The RSUs are scheduled to vest in full on May 27, 2027, at which point the director will receive an equivalent number of common shares.

Industry Context

StockSavvy.ai notes that equity grants to board members are a standard corporate governance practice in the biotechnology sector to ensure director alignment with long-term company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard director compensation packages for mid-to-large cap biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of the 2,567 RSUs on May 27, 2027.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Trading, Restricted Stock Units, Director Compensation